rs397508686

Variant summary

Our verdict is Pathogenic. Variant got 13 ACMG points: 13P and 0B. PM1PM2PM4_SupportingPP5_Very_Strong

The ENST00000003084.11(CFTR):​c.413_415dup​(p.Leu138dup) variant causes a inframe insertion change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.00000186 in 1,613,658 control chromosomes in the GnomAD database, with no homozygous occurrence. Variant has been reported in ClinVar as Pathogenic (★★★). Synonymous variant affecting the same amino acid position (i.e. L137L) has been classified as Likely benign.

Frequency

Genomes: 𝑓 0.0000066 ( 0 hom., cov: 32)
Exomes 𝑓: 0.0000014 ( 0 hom. )

Consequence

CFTR
ENST00000003084.11 inframe_insertion

Scores

Not classified

Clinical Significance

Pathogenic reviewed by expert panel P:9O:1

Conservation

PhyloP100: 1.64
Variant links:
Genes affected
CFTR (HGNC:1884): (CF transmembrane conductance regulator) This gene encodes a member of the ATP-binding cassette (ABC) transporter superfamily. The encoded protein functions as a chloride channel, making it unique among members of this protein family, and controls ion and water secretion and absorption in epithelial tissues. Channel activation is mediated by cycles of regulatory domain phosphorylation, ATP-binding by the nucleotide-binding domains, and ATP hydrolysis. Mutations in this gene cause cystic fibrosis, the most common lethal genetic disorder in populations of Northern European descent. The most frequently occurring mutation in cystic fibrosis, DeltaF508, results in impaired folding and trafficking of the encoded protein. Multiple pseudogenes have been identified in the human genome. [provided by RefSeq, Aug 2017]

Genome browser will be placed here

ACMG classification

Classification made for transcript

Verdict is Pathogenic. Variant got 13 ACMG points.

PM1
In a hotspot region, there are 3 aminoacids with missense pathogenic changes in the window of +-8 aminoacids around while only 0 benign, 13 uncertain in ENST00000003084.11
PM2
Very rare variant in population databases, with high coverage;
PM4
Nonframeshift variant in NON repetitive region in ENST00000003084.11. Strenght limited to Supporting due to length of the change: 1aa.
PP5
Variant 7-117531036-C-CCTA is Pathogenic according to our data. Variant chr7-117531036-C-CCTA is described in ClinVar as [Pathogenic]. Clinvar id is 53905.Status of the report is reviewed_by_expert_panel, 3 stars.

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect #exon/exons MANE Protein UniProt
CFTRNM_000492.4 linkuse as main transcriptc.413_415dup p.Leu138dup inframe_insertion 4/27 ENST00000003084.11 NP_000483.3

Ensembl

Gene Transcript HGVSc HGVSp Effect #exon/exons TSL MANE Protein Appris UniProt
CFTRENST00000003084.11 linkuse as main transcriptc.413_415dup p.Leu138dup inframe_insertion 4/271 NM_000492.4 ENSP00000003084 P2P13569-1

Frequencies

GnomAD3 genomes
AF:
0.00000657
AC:
1
AN:
152132
Hom.:
0
Cov.:
32
show subpopulations
Gnomad AFR
AF:
0.00
Gnomad AMI
AF:
0.00
Gnomad AMR
AF:
0.00
Gnomad ASJ
AF:
0.00
Gnomad EAS
AF:
0.00
Gnomad SAS
AF:
0.00
Gnomad FIN
AF:
0.00
Gnomad MID
AF:
0.00
Gnomad NFE
AF:
0.0000147
Gnomad OTH
AF:
0.00
GnomAD3 exomes
AF:
0.00000399
AC:
1
AN:
250744
Hom.:
0
AF XY:
0.00000738
AC XY:
1
AN XY:
135488
show subpopulations
Gnomad AFR exome
AF:
0.00
Gnomad AMR exome
AF:
0.00
Gnomad ASJ exome
AF:
0.00
Gnomad EAS exome
AF:
0.00
Gnomad SAS exome
AF:
0.00
Gnomad FIN exome
AF:
0.0000463
Gnomad NFE exome
AF:
0.00
Gnomad OTH exome
AF:
0.00
GnomAD4 exome
AF:
0.00000137
AC:
2
AN:
1461526
Hom.:
0
Cov.:
31
AF XY:
0.00000275
AC XY:
2
AN XY:
727040
show subpopulations
Gnomad4 AFR exome
AF:
0.00
Gnomad4 AMR exome
AF:
0.00
Gnomad4 ASJ exome
AF:
0.00
Gnomad4 EAS exome
AF:
0.00
Gnomad4 SAS exome
AF:
0.00
Gnomad4 FIN exome
AF:
0.0000187
Gnomad4 NFE exome
AF:
8.99e-7
Gnomad4 OTH exome
AF:
0.00
GnomAD4 genome
AF:
0.00000657
AC:
1
AN:
152132
Hom.:
0
Cov.:
32
AF XY:
0.0000135
AC XY:
1
AN XY:
74306
show subpopulations
Gnomad4 AFR
AF:
0.00
Gnomad4 AMR
AF:
0.00
Gnomad4 ASJ
AF:
0.00
Gnomad4 EAS
AF:
0.00
Gnomad4 SAS
AF:
0.00
Gnomad4 FIN
AF:
0.00
Gnomad4 NFE
AF:
0.0000147
Gnomad4 OTH
AF:
0.00
Bravo
AF:
0.00000378

ClinVar

Significance: Pathogenic
Submissions summary: Pathogenic:9Other:1
Revision: reviewed by expert panel
LINK: link

Submissions by phenotype

Cystic fibrosis Pathogenic:7Other:1
Likely pathogenic, criteria provided, single submittercurationInstitute of Human Genetics, University of Leipzig Medical CenterSep 05, 2022This variant was identified in 4 unrelated patients with a clinically confirmed diagnosis of cystic fibrosis. The variant was classified in the context of a project re-classifying variants in the German Cystic Fibrosis Registry (Muko.e.V.). Link: https://www.muko.info/angebote/qualitaetsmanagement/register/cf-einrichtungen/mukoweb. Criteria applied: PS3_SUP, PM2_SUP, PM3_STR, PM4_SUP, PP4 -
Pathogenic, criteria provided, single submitterclinical testingNorth West Genomic Laboratory Hub, Manchester University NHS Foundation TrustOct 29, 2019Criteria Codes: PM2 PM3_VStr PM4 -
Pathogenic, criteria provided, single submitterclinical testingLabcorp Genetics (formerly Invitae), LabcorpOct 12, 2023This variant, c.413_415dup, results in the insertion of 1 amino acid(s) of the CFTR protein (p.Leu138dup), but otherwise preserves the integrity of the reading frame. This variant is present in population databases (rs752803445, gnomAD 0.004%). This variant has been observed in individual(s) with CFTR-related conditions (PMID: 9272157, 16189704, 28546993, 30548586). In at least one individual the data is consistent with being in trans (on the opposite chromosome) from a pathogenic variant. This variant is also known as 546insCTA and c.411_412insCTA. ClinVar contains an entry for this variant (Variation ID: 53905). Algorithms developed to predict the effect of variants on protein structure and function are not available or were not evaluated for this variant. Experimental studies have shown that this variant affects CFTR function (PMID: 30046002). For these reasons, this variant has been classified as Pathogenic. -
Pathogenic, reviewed by expert panelresearchCFTR2Aug 31, 2018- -
not provided, no classification providedliterature onlyClinVar Staff, National Center for Biotechnology Information (NCBI)-- -
Pathogenic, no assertion criteria providedclinical testingNatera, Inc.Sep 16, 2020- -
Pathogenic, criteria provided, single submitterclinical testingWomen's Health and Genetics/Laboratory Corporation of America, LabCorpFeb 21, 2024Variant summary: CFTR c.413_415dupTAC (p.Leu138dup) results in an in-frame duplication that is predicted to duplicate 1 amino acids into the encoded protein. The variant allele was found at a frequency of 4e-06 in 250744 control chromosomes. c.413_415dupTAC has been reported in the literature in multiple individuals affected with Cystic Fibrosis (e.g. Behar_2017, Guo_2018, McGinniss_2005, Petrova_2019, Walkowiak_2001). These data indicate that the variant is very likely to be associated with disease. Experimental evidence evaluating an impact on protein function demonstrated the variant confers residual function 1.6% of wild-type (Han_2018). The following publications have been ascertained in the context of this evaluation (PMID: 9272157, 11589722, 16189704, 28546993, 30046002, 30548586, 30558651).ClinVar contains an entry for this variant (Variation ID: 53905). Based on the evidence outlined above, the variant was classified as pathogenic. -
Pathogenic, criteria provided, single submitterclinical testingAmbry GeneticsApr 08, 2024The c.413_415dupTAC pathogenic mutation (also known as p.L138dup), located in coding exon 4 of the CFTR gene, results from an in-frame duplication of TAC at nucleotide positions 413 to 415. This results in the duplication of an extra residue between codons 138 and 139. In our laboratory, this variant has been detected in trans with a pathogenic mutation in CFTR in an individual with intermediate sweat chloride levels (Ambry internal data). In an analysis of 40 CFTR mutations in Russian cystic fibrosis (CF) patients, this variant (reported as L138ins) was detected in 1.8% of the chromosomes (Adyan TA et al. Russ J Genet, 2018 Oct;54:1235-1244). This mutation was reported in a Polish male with congenital bilateral absence of the vas deferens (CBAVD) in conjunction with a 5T allele (Dörk T et al. Hum. Genet., 1997 Sep;100:365-77). This alteration was also described in an individual with CF in conjunction with the c.3717+12191C>T mutation; however, the phase is unclear (Behar DM et al. Mol Genet Genomic Med, 2017 May;5:223-236). Based on internal structural analysis, this pathogenic variant is anticipated to result in a significant decrease in structural stability (Liu F et al. Cell, 2017 Mar;169:85-95.e8). In addition, human CF bronchial epithelial (CFBE) cells stably expressing this mutation (reported as L138ins) had only 1.6% of CFTR function, compared to cells expressing wild-type CFTR protein (Han ST et al. JCI Insight, 2018 Jul;3:). Furthermore, the duplication has an overall frequency of approximately 0.0004% (1/250744) in the Genome Aggregation Database (gnomAD) (Lek M et al. Nature, 2016 08;536:285-91). Based on the supporting evidence, this alteration is interpreted as a disease-causing mutation. -
not provided Pathogenic:1
Pathogenic, criteria provided, single submitterclinical testingMayo Clinic Laboratories, Mayo ClinicFeb 25, 2021PS3, PS4_Moderate, PM2, PM3, PM4, PP5 -
Bronchiectasis with or without elevated sweat chloride 1 Pathogenic:1
Pathogenic, criteria provided, single submitterclinical testingBaylor GeneticsDec 28, 2023- -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction

Splicing

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

LitVar

Below is the list of publications found by LitVar. It may be empty.

Other links and lift over

dbSNP: rs397508686; hg19: chr7-117171090; API